1Q EARNINGS: AbbVie buoyed by Humira, touts hepatitis C program
This article was originally published in Scrip
Executive Summary
A 17.5% jump in Humira (adalimumab) sales to $2.6bn in the first quarter kept AbbVie's net product sales in positive territory as therapies for controlling cholesterol plunged due to generic competition, putting greater emphasis on the company's future in hepatitis C.